Lutetium (177Lu) vipivotide tetraxetan, also known as Lutathera®, is a radiopharmaceutical agent approved by the FDA for the treatment of certain types of cancer. It is a type of radiotherapy, which uses radiation to destroy cancer cells. The primary active ingredient of Lutathera is lutetium-177, a radioactive isotope, which is bound to a small molecule called vipivotide tetraxetan. This molecule helps to improve the way the radiation is delivered to the tumor, targeting it more accurately. Lutathera is used in the treatment of certain types of neuroendocrine tumors, such as gastroenteropancreatic and bronchial tumors, as well as some types of prostate and ovarian cancer. It is administered intravenously and is typically given in four doses over the course of four months. The effects of Lutathera can be seen within a few weeks of treatment, and its effects can last for several months.
Lutetium (177Lu) vipivotide tetraxetan, also sold under the brand name Pluvicto, is a medication used for a specific type of prostate cancer [1]. Here's a breakdown of what it targets and how it works:
- Cancer Target: This medication is designed to treat metastatic castration-resistant prostate cancer (mCRPC) that is positive for prostate-specific membrane antigen (PSMA) [1, 2]. PSMA is a protein on the surface of some prostate cancer cells.
- Targeted Radioligand Therapy: Lutetium (177Lu) vipivotide tetraxetan works in a two-pronged approach:
- Part 1: Targeting PSMA: The drug combines two key components. One part, called vipivotide tetraxetan, acts like a guided missile that seeks out and binds to PSMA on prostate cancer cells [1, 2].
- Part 2: Radiation Delivery: The other part is lutetium-177 (177Lu), a radioactive isotope. By attaching to the PSMA-targeting molecule, 177Lu delivers radiation directly to cancer cells, damaging their DNA and potentially causing cell death [1, 2].
Benefits of Targeted Therapy:
- This targeted approach aims to deliver radiation specifically to cancer cells, potentially reducing side effects on healthy tissues compared to traditional radiation therapy [2].
Important Considerations:
- Not for All Prostate Cancers: Lutetium (177Lu) vipivotide tetraxetan is only effective for PSMA-positive mCRPC and has gone through specific prior treatments [2].
- Approval and Availability: The medication was approved by the FDA in 2022 and may not be available in all regions. It's typically administered and monitored by healthcare professionals in specialized settings due to the radioactive nature of the drug [1].
- Potential Side Effects: As with any medication, there can be side effects. Fatigue, dry mouth, nausea, and decreased appetite are some of the reported side effects [1].